Journal article
Megestrol acetate plus minidose diethylstilbestrol in the treatment of carcinoma of the prostate.
Abstract
A multicenter randomized trial comparing megestrol acetate 120 mg/d, plus diethylstilbestrol (DES) 0.1 to 3 mg/d in patients with stage D2 prostate cancer was undertaken to compare the efficacy and toxicity of these two regimens. Pretreatment characteristics, including pathologic grade, performance status, age, and disease-related symptoms were similar in the two groups. Of 81 patients who have been entered in the study, 77 are evaluable for …
Authors
Venner PM; Klotz PG; Klotz LH; Stewart DJ; Davis IR; Orovan WL; Ramsey EW
Journal
Seminars in Oncology, Vol. 15, No. 2 Suppl 1, pp. 62–67
Publication Date
April 1988
ISSN
0093-7754